A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi-Center, International Study of Durvalumab Given Concurrently With Definitive Chemoradiation Therapy in Patients With Locally Advanced, Unresectable Esophageal Squamous Cell Carcinoma (KUNLUN)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 23 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Durvalumab (Primary) ; Capecitabine; Cisplatin; Fluorouracil
Indications Carcinoma; Oesophageal cancer; Squamous cell cancer
Focus Registrational; Therapeutic Use
Acronyms KUNLUN
Sponsors AstraZeneca; AstraZeneca AB

Most Recent Events

10 Nov 2023 Status changed from recruiting to active, no longer recruiting.
23 Jan 2022 This trial has been discontinued in Netherland, according to European Clinical Trials Database record.
22 Jan 2022 Study design has been released at the 2022 Gastrointestinal Cancers Symposium

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight